Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Q1 2021 Financials /Operational update
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(36)
•••
Comment by LithLoveron May 17, 2021 9:14pm
94 Views
Post# 33219248

RE:RE:RE:RE:RE:RE:RE:Q1 2021 Financials /Operational update

RE:RE:RE:RE:RE:RE:RE:Q1 2021 Financials /Operational updateRead the financials out on Sedar shows start and ending cash position. 


kodiakup wrote: - I don't know where you see 7 million in banks when they have 0.08 / loss shares ...for the last quarter.....


Financial Overview
 
For the fiscal year ended 31 December 2020,StageZero Life Sciences Ltd revenues increased from $139Kto $4.2M. Net loss increased 97% to $6.9M. Revenues reflectan increase in demand for the Company's products andservices due to favorable market conditions. Higher netloss reflects Salaries and short-term benefits increase of18% to $1.7M (expense), Rent increase of 26% to $14K(expense).

Employees: 51 as of Dec 31, 2020
 
Reporting Currency: U.S. Dollars
Enterprise value: $37.91M as of Dec 31, 2020
Annual revenue (TTM): $5.02M as of Dec 31, 2020
EBITDA (TTM): -$3.70M as of Dec 31, 2020
Net annual income (TTM): -$8.31M as of Dec 31, 2020
Free cash flow (TTM): -$3.80M as of Dec 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 60,247,857 as of May 3, 2021



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities